NXgenPort (NGP), has designed an innovative and transformative technology to maximize remote care in cancer patients requiring an implantable chemo-port catheter. Combining proven chemo-port efficacy with microchip and sensor technology, NGP measures, monitors and reports physiological body functions in vivo over the course of disease and treatment.
In this episode, Founder and CEO Kathy Skinner shares the details of how this port advances care for a very important patient population and how its quickly gaining momentum.
Dr. Michael Meighen is a physician who is board certified in Physiatry and Pain Medicine. He is the author of #1 Best Selling Book...
In this episode, host Tobin Arthur is joined by colleagues Katie Richardson, MD and Mike Schmanske interviewing startup Founder Kate Dilligan of Cooler Heads....
DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The...
